Hantz Financial Services Inc. Has $1.17 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Hantz Financial Services Inc. lifted its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 71.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 37,388 shares of the company’s stock after acquiring an additional 15,620 shares during the period. Hantz Financial Services Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,167,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. AQR Capital Management LLC grew its stake in Teva Pharmaceutical Industries by 24.6% during the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after buying an additional 4,732 shares in the last quarter. Focus Partners Wealth grew its stake in Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after buying an additional 1,739 shares in the last quarter. Franklin Resources Inc. acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth about $255,000. Flow Traders U.S. LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth about $238,000. Finally, Cerity Partners LLC grew its stake in Teva Pharmaceutical Industries by 2.9% during the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after buying an additional 1,291 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on TEVA shares. The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Scotiabank increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Finally, Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Insiders Place Their Bets

In related news, EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the sale, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. This trade represents a 34.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the completion of the sale, the executive vice president directly owned 172,184 shares of the company’s stock, valued at approximately $6,131,472.24. The trade was a 47.09% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 934,459 shares of company stock worth $31,122,931 in the last quarter. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.0%

Teva Pharmaceutical Industries stock opened at $34.60 on Thursday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The firm has a 50 day moving average price of $32.15 and a two-hundred day moving average price of $31.23. The firm has a market cap of $39.78 billion, a price-to-earnings ratio of 26.01, a PEG ratio of 3.35 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.